Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

Platform-enabled Experiences Built to Manage Complexity

Introducing the Medidata Experiences—digital solutions to streamline clinical trial processes, cut costs, speed up therapy evolution, and ultimately save patients’ lives.

FEATURED CONTENT

DATA EXPERIENCE

The Medidata Data Experience connects every part of the clinical data process. From study build to data capture, database lock, and regulatory submission, it leverages built-in AI and automation to simplify workflows, reduce manual effort, improve data quality, and shorten trial timelines—turning raw data into real insights faster.
  • Rave Coder provides medical coding for verbatim terms from Rave EDC and external sources using the MedDRA, WHODrug and JDrug dictionaries. Rave Coder centralizes and streamlines medical coding, delivering key benefits to sites, coding specialists and data managers.

  • Source data verification (SDV) is a critical activity within clinical trial monitoring, yet the traditional approach focused on 100% SDV is limited in its ability to quickly identify issues and prevent them from recurring. Rave TSDV (Targeted SDV), unified with Rave EDC, enables CRAs to focus on critical to quality (CtQ) factors identified within risk management activities.

  • Medidata RBQM (Risk-Based Quality Management) provides the technology and experience to transform your approach to clinical operations towards risk-based study execution models. Now you can continuously monitor data from anywhere, allowing you to innovate and optimize your approach to trial design, physical and virtual  interactions with sites, and holistic portfolio strategy.

  • Medidata Adjudicate is part of the Medidata Clinical Cloud™, and offers a cloud-based, end-to-end solution, with easily configurable modules enabling quick setup to manage endpoint adjudication in clinical trials. Medidata Adjudicate supports investigator sites, sponsors, CROs, data managers, and the CEC in collecting, managing, organizing, adjudicating and submitting clinical endpoint data.

  • Experience a transformative AI-powered data quality management solution that unifies study teams by providing seamless access to data from all clinical data sources.

PATIENT EXPERIENCE

The Medidata Patient Experience provides an end-to-end technology solution throughout the entire clinical trial journey. From patient recruitment to in-trial activities and study completion, Medidata provides a full suite of capabilities, all centralized on a single unified platform. This approach simplifies the experience for patients while optimizing workflows for sites.

STUDY EXPERIENCE

The Medidata Study Experience accelerates clinical trial design and management by seamlessly connecting workflows, data, and teams. Powered by AI and advanced analytics, it enables sponsors to simulate and optimize trial designs before committing resources. It streamlines critical activities like protocol design, site feasibility, budgeting, and execution, and delivers actionable insights that reduce risk, improve decision-making, eliminate redundancies, and keep operations on track

OTHER

CONTACT INFORMATION

Medidata, a Dassault Systemes company

350 Hudson Street, 9th Floor

New York, NY 10014

UNITED STATES

Phone: 732-997-9172

Contact: Louis Gutierrez